High Frequency of Bone Marrow Involvement in Intravascular Large B-Cell Lymphoma

Wang, Jianchao; Ding, Wenshuang; Gao, Limin; Yao, Wenqing; Chen, Min; Zhao, Sha; Liu, Weiping; Zhang, Wenyan

doi:10.1177/1066896916665203

Cited by 14 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with previous reports [6,18,23,24], we found comparable age at diagnosis (67 years old) but slightly older than other Asians [4,11,20]. A slight male predominance which is consistent with studies from Thailand [11,20], Taiwan [4], and China [22] was observed in our study, although studies by Murase et al [24] and Rajyaguru et al [21] showed no gender preference. Fever was found in the majority of patients while neurologic abnormalities were also relatively common in this study.…”

supporting

confidence: 93%

“…Our results confirmed the variable morphology of cutaneous manifestations as seen in other studies [2]. Regarding bone marrow study, although a recent series of IVLBCL patients diagnosed by random skin biopsy showed no BM involvement [11], we found approximately 35% with BM infiltration which is consistent with previous studies ranging from 26.7% to 100% [4,6,20,22,24,26,27]. Additionally, we found that increased sera LDH and ferritin were exceedingly common in IVLBCL patients, consistent with earlier publications reporting 75%-100% of elevated LDH [5,11,20,22,23,26] and 80-100% of elevated ferritin [4,26] in IVLBCL patients.…”

supporting

confidence: 92%

“…BioMed Research International of our knowledge, our study is among the few highlighting that IHC could be utilized as a prognostic factor in IVLBCL patients [4,22]. In agreement with previous reports [6,18,23,24], we found comparable age at diagnosis (67 years old) but slightly older than other Asians [4,11,20].…”

supporting

confidence: 92%

See 2 more Smart Citations

Prognostic Value of Concurrent Expression of C‐MYC and BCL2 in Intravascular Large B‐Cell Lymphoma: A 10‐Year Retrospective Study

Boonsakan

Iamsumang

Chantrathammachart

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Intravascular large B-cell lymphoma (IVLBCL) is a variant of extranodal diffuse large B-cell lymphoma (DLBCL), characterized by the presence of a B-lymphoma cell in the lumina of small blood vessels or capillaries. Due to its extremely variable clinical manifestations, IVLBCL typically results in a delayed diagnosis and poor disease prognosis. Skin biopsy, particularly random skin biopsy, has shown a potential role in the diagnosis of IVLBCL. However, information of clinicopathological features in patients with IVLBCL diagnosed by skin biopsy is limited. Objectives. To study the clinicopathological features in relation to immunohistochemical features and to identify prognostic factors in IVLBCL patients diagnosed by skin biopsy. Materials and Methods. Clinical characteristics; laboratory, histological, and immunohistochemical findings; and therapeutic response of all biopsy-confirmed IVLBCL patients during the years 2008-2017 were retrospectively reviewed. Results. The mean age was 67.4 (±9.8) years. Fever was the most common presenting symptom, accounting for 64.7%. Cutaneous and bone marrow involvement was found in 23.5% and 35.3% of patients, respectively. Patients receiving R-CHOP showed more favorable therapeutic outcome. C-MYC/BCL2 double expressors showed significantly higher incidence rate to mortality compared with nondouble expressors (p=0.042). One-year and two-year overall survival rates were 67.2% and 53.8%, respectively. Conclusions. Skin biopsy is an effective diagnostic method for IVLBCL. Concurrent expression of C-MYC and BCL2 may be a useful prognostic indicator and should be performed in order to predict the prognosis in IVLBCL patients.

show abstract

supporting

confidence: 93%

supporting

confidence: 92%

See 1 more Smart Citation

Prognostic Value of Concurrent Expression of C‐MYC and BCL2 in Intravascular Large B‐Cell Lymphoma: A 10‐Year Retrospective Study

Boonsakan

Iamsumang

Chantrathammachart

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Unlike other lymphomas of the CNS, 14 , 16 BBB-penetrating drugs, such as MTX and cytarabine, are rarely included in chemotherapy regimens for CNS-involved IVLBCL. As the number of patients treated with BBB-penetrating drugs was small, our analysis failed to reach a definitive conclusion.…”

Section: Discussionmentioning

confidence: 99%

<p>Prognosis of Intravascular Large B Cell Lymphoma (IVLBCL): Analysis of 182 Patients from Global Case Series</p>

Liu¹,

Zhang²,

Zhu³

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose This study provides an overview of the prognosis of intravascular large B cell lymphoma (IVLBCL) over the past 10 years and analyzes the possible relevant factors. Patients and Methods We conducted a literature search of case reports, case series, and retrospective studies of IVLBCL published from January 2008 to July 2018. After excluding inappropriate data, 103 publications were selected for the analysis. Statistical analyses of different treatment modalities, the effect of blood–brain barrier (BBB)-penetrating drugs, and prognostic factors for outcomes were performed. Results In total, 182 pathologically confirmed cases of IVLBCL were included in our study. The results revealed that the 1- and 3-year overall survival rates were 42.3 and 11.5%, respectively, whereas the median overall survival was 340 days. Overall survival (450 days vs 180 days) and progression-free survival (420 days vs 150 days) were significantly longer in patients who received rituximab-containing regimens than in those treated with other regimens. For IVLBCL involving the CNS, regimens containing BBB-penetrating drugs failed to provide an additional survival benefit. In addition, lactic dehydrogenase levels ≥700 U/L, CNS involvement, and hemophagocytic syndrome were identified as unfavorable risk factors in patients with IVLBCL, whereas skin involvement appeared to be a protective factor. Conclusion Rituximab-containing chemotherapy can improve the outcomes of patients with IVLBCL, but the prognosis remains unsatisfactory. Treatment regimens containing BBB-penetrating drugs failed to improve outcomes in patients with CNS-involved IVLBCL. Several factors affect the prognosis of patients with IVLBCL, and further research on the underlying mechanisms is needed.

show abstract

“…of IVLBCL in a bone marrow biopsy. 8 In our case, however, bone marrow biopsy results were negative.…”

mentioning

confidence: 72%

Intravascular Large B-Cell Lymphoma: A Continuing Clinical Enigma

Lique²

2017

PJP

View full text Add to dashboard Cite

Intravascular large B-cell lymphoma (IVLBCL) is a rare form of extranodal diffuse large B-cell lymphoma characterized by the proliferation of lymphoma cells in the lumen of small blood vessels. Clinical presentation varies among reported cases and diagnosis can be challenging for both clinicians and pathologists. We report a case of a 64-year-old female with a history of prolonged fever. Diagnosis was suspected clinically due to thrombocytopenia and elevated serum lactate dehydrogenase after exhausting work-up for an infectious etiology. IVLBCL was established on post-mortem examination upon finding infiltration of CD20-positive neoplastic cells in several organs in the absence of lymph node involvement.

show abstract

High Frequency of Bone Marrow Involvement in Intravascular Large B-Cell Lymphoma

Cited by 14 publications

References 35 publications

Prognostic Value of Concurrent Expression of C‐MYC and BCL2 in Intravascular Large B‐Cell Lymphoma: A 10‐Year Retrospective Study

Prognostic Value of Concurrent Expression of C‐MYC and BCL2 in Intravascular Large B‐Cell Lymphoma: A 10‐Year Retrospective Study

<p>Prognosis of Intravascular Large B Cell Lymphoma (IVLBCL): Analysis of 182 Patients from Global Case Series</p>

Intravascular Large B-Cell Lymphoma: A Continuing Clinical Enigma

Contact Info

Product

Resources

About